Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma
Status: Archived
Winship Cancer Institute of Emory University
mi
from
Egleston, GA
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma
Status: Archived
Updated: 1/1/1970
Winship Cancer Institute of Emory University
mi
from
Egleston, GA
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma
Status: Archived
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma
Status: Archived
Updated: 1/1/1970
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma
Status: Archived
Josephine Ford Cancer Center at Henry Ford Hospital
mi
from
Detroit, MI
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma
Status: Archived
Updated: 1/1/1970
Josephine Ford Cancer Center at Henry Ford Hospital
mi
from
Detroit, MI
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma
Status: Archived
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma
Status: Archived
Updated: 1/1/1970
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma
Status: Archived
Taussig Cancer Center, Cleveland Clinic Foundation
mi
from
Cleveland, OH
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma
Status: Archived
Updated: 1/1/1970
Taussig Cancer Center, Cleveland Clinic Foundation
mi
from
Cleveland, OH
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma
Status: Archived
Abamson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma
Status: Archived
Updated: 1/1/1970
Abamson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
A Phase I Study of PRK787/ZK 222584 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
A Phase I Study of PRK787/ZK 222584 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
A Phase I Study of PRK787/ZK 222584 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
A Phase I Study of PRK787/ZK 222584 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Rhode Island Hospital
mi
from
Providence, RI
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
Rhode Island Hospital
mi
from
Providence, RI
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
Glendale, AZ
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Glendale, AZ
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
Fayetteville, AR
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Fayetteville, AR
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
Anaheim, CA
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Anaheim, CA
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
Aurora, CO
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Aurora, CO
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Yale University School of Medicine
mi
from
New Haven, CT
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
Yale University School of Medicine
mi
from
New Haven, CT
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
McFarland Clinic, PC
mi
from
Ames, IA
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
McFarland Clinic, PC
mi
from
Ames, IA
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
Indianapolis, IN
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Indianapolis, IN
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
Westwood, KA
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Westwood, KA
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
Louisville, KY
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Louisville, KY
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
Baton Rouge, LA
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Baton Rouge, LA
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Georgetown Univ Med Ctr
mi
from
Washington,
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
Georgetown Univ Med Ctr
mi
from
Washington,
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
Jackson, MS
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Jackson, MS
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
Chesterfield, MO
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Chesterfield, MO
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
Grand Island, NE
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Grand Island, NE
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
Las Vegas, NV
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Las Vegas, NV
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
Albuquerque, NM
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Albuquerque, NM
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
Klamath Falls, OR
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Klamath Falls, OR
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
Charleston, SC
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Charleston, SC
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
Austin, TX
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Austin, TX
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
Kennewick, WA
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Kennewick, WA
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
GSK Investigational Site
mi
from
La Crosse, WI
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
La Crosse, WI
Side Effects of Radiation Therapy in Young Patients With CNS Tumors
An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Side Effects of Radiation Therapy in Young Patients With CNS Tumors
An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin
Phase I/II Trial of Sequential Paclitaxel/Ifosfamide Followed by Dose-Escalated, Dose-Intensive Carboplatin, Paclitaxel and Ifosfamide With Stem Cell Support in Cisplatin-Resistant Germ Cell Tumor Patients
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin
Phase I/II Trial of Sequential Paclitaxel/Ifosfamide Followed by Dose-Escalated, Dose-Intensive Carboplatin, Paclitaxel and Ifosfamide With Stem Cell Support in Cisplatin-Resistant Germ Cell Tumor Patients
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
A Phase I Trial of Nelfinavir (Viracept®) in Adults With Solid Tumors
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
A Phase I Trial of Nelfinavir (Viracept®) in Adults With Solid Tumors
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Phase I Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
Phase I, Open-Label, Dose-Escalation,Safety Study of the Combination of Sunitinib and Radiation Therapy for the Treatment of Patients With Cancer
Status: Archived
Thomas Jefferson Hospital
mi
from
Philadelphia, PA
Phase I Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
Phase I, Open-Label, Dose-Escalation,Safety Study of the Combination of Sunitinib and Radiation Therapy for the Treatment of Patients With Cancer
Status: Archived
Updated: 1/1/1970
Thomas Jefferson Hospital
mi
from
Philadelphia, PA
Enzastaurin and Carboplatin in Treating Patients With Recurrent or Refractory Primary Brain Tumors
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Enzastaurin and Carboplatin in Treating Patients With Recurrent or Refractory Primary Brain Tumors
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Study of Patients With Cancer or Precancerous Conditions
Treatment of Children With Cancer
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Study of Patients With Cancer or Precancerous Conditions
Treatment of Children With Cancer
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Identification of Key Blood Molecular Markers for Immunotherapy
Identification of Key Blood Molecular Markers for Immunotherapy
Status: Archived
Stanford University School of Medicine
mi
from
Stanford, CA
Identification of Key Blood Molecular Markers for Immunotherapy
Identification of Key Blood Molecular Markers for Immunotherapy
Status: Archived
Updated: 1/1/1970
Stanford University School of Medicine
mi
from
Stanford, CA
A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
Phase II Trial for Patients With Glioblastoma Multiforme (GBM) Treated With Gliadel Followed by Avastin Plus Irinotecan
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
Phase II Trial for Patients With Glioblastoma Multiforme (GBM) Treated With Gliadel Followed by Avastin Plus Irinotecan
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Children's Hospital
mi
from
Pittsburgh, PA
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Children's Hospital
mi
from
Pittsburgh, PA
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Children's Nutrition Research Center, Baylor College of Medicine
mi
from
Houston, TX
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Children's Nutrition Research Center, Baylor College of Medicine
mi
from
Houston, TX
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Children's Hospital - Boston
mi
from
Boston, MA
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Children's Hospital - Boston
mi
from
Boston, MA
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Indiana University Adult Psychiatry Clinic
mi
from
Indianapolis, IN
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Indiana University Adult Psychiatry Clinic
mi
from
Indianapolis, IN
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Siteman Cancer Center
mi
from
St. Louis, MO
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Siteman Cancer Center
mi
from
St. Louis, MO
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY